Table 4 Thrombocytopenia and venous thromboembolism following COVID-19 vaccine booster dose.
Primary series/booster vaccine | No. of booster doses | Event (1–21 day) | Crude risk per 100,000 doses (95% CI) | Event (> 21 day) | Crude risk per 100,000 doses (95% CI) |
|---|---|---|---|---|---|
Thrombocytopenia | |||||
BNT162b2 | |||||
BNT162b2 | 5,312,389 | 17 | 0.32 (0.19 to 0.51) | 44 | 0.83 (0.60 to 1.11) |
CoronaVac | 16,003 | – | – | – | – |
ChAdOx1 | 334,895 | < 3 | ** | < 3 | ** |
CoronaVac | |||||
BNT162b2 | 5,966,652 | 31 | 0.52 (0.35 to 0.74) | 49 | 0.82 (0.61 to 1.09) |
CoronaVac | 1,103,513 | 4 | 0.36 (0.10 to 0.93) | 3 | 0.27 (0.06 to 0.79) |
ChAdOx1 | 465,243 | – | – | < 3 | ** |
ChAdOx1 | |||||
BNT162b2 | 713,579 | < 3 | ** | – | – |
CoronaVac | 2461 | – | – | – | – |
ChAdOx1 | 730,109 | 3 | 0.41 (0.08 to 1.20) | – | – |
Venous thromboembolism | |||||
BNT162b2 | |||||
BNT162b2 | 5,312,389 | 30 | 0.56 (0.38 to 0.81) | 41 | 0.77 (0.55 to 1.05) |
CoronaVac | 16,003 | – | – | – | – |
ChAdOx1 | 334,895 | < 3 | ** | < 3 | ** |
CoronaVac | |||||
BNT162b2 | 5,966,652 | 33 | 0.55 (0.38 to 0.78) | 61 | 1.02 (0.78 to 1.31) |
CoronaVac | 1,103,513 | – | – | 5 | 0.45 (0.15 to 1.06) |
ChAdOx1 | 465,243 | – | – | < 3 | ** |
ChAdOx1 | |||||
BNT162b2 | 713,579 | 3 | 0.42 (0.09 to 1.23) | < 3 | ** |
CoronaVac | 2461 | – | – | – | – |
ChAdOx1 | 730,109 | – | – | – | – |
